Skip to content
Menu

Innoviva, Inc. INVA

Full chart Compare
Set alert

Price alert · INVA

All alert types
18.41 USD 0.00 (+0.00%)

Regular-session close

18.41 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

18.33 Day range 18.79
18.19 52-week range 25.15
YTD
-7.90%
1 year
-13.00%

5D -0.51 (-2.70%)

18.5019WedThuFriMonTue18.38
Market cap
1.31B
Revenue (ttm)
438.32M
Profit margin
44.13%
EPS (ttm)
2.35
Shares out
71.08M
P/E ratio
7.83
Forward P/E
8.33
YTD return
-7.90%
1-year return
-13.00%
50-day average
20.48
Volume
1.15M
Avg volume
855.55K
Open
18.41
Previous close
18.41
Day's range
18.33 – 18.79
52-week range
18.19 – 25.15
Beta
0.37
Analysts
Buy
Price target
33.83 (+83.8%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
21.84
Enterprise value
1.05B
PEG ratio
2.80
Price / sales
2.99
Price / book
1.16
Revenue growth
-1.60%
Free cash flow
121.16M
Total cash
590.06M
Total debt
331.04M
Return on equity
18.02%
Short % of float
14.28%

Fundamental scorecard

16 of 25 checks passed on INVA’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 4 of 5
  • Growth 3 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
INVA Revenue — quarterly 106.12M
INVA Net income — quarterly -73.89M
INVA EPS — quarterly -1.03

Earnings

INVA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20260.47———
Nov 4, 2026Sep 30, 20260.515-1.03-1.54-300.00%
Aug 5, 2026Jun 30, 20260.4361.14+0.70+161.47%
May 6, 2026Mar 31, 20260.430.44+0.01+2.33%
Feb 25, 2026Dec 31, 20250.341.94+1.60+470.59%
Nov 5, 2025Sep 30, 20250.461.08+0.62+134.78%

Upgrades / downgrades

INVA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 18, 2026Piper Sandlerinit—Overweight
Nov 5, 2026OppenheimermainOutperformOutperform
Aug 7, 2026Cantor FitzgeraldmainOverweightOverweight
Jun 22, 2026BTIGmainBuyBuy
Jun 1, 2026HC Wainwright & Co.reitBuyBuy
May 26, 2026BTIGreitBuyBuy

About Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
inva.com

News

Your note

Sign in to keep a note on INVA — it syncs with the Stock Master app.

Insider holders

INVA insider holders
InsiderRelationLatest transactionDateShares held
BASSO STEPHENChief Financial OfficerStock Award(Grant)May 14, 202688,571
DENNER ALEXANDER JBeneficial Owner of more than 10% of a Class of SecuritySaleMar 5, 20250
DIPAOLO MARK ADirectorStock Award(Grant)May 3, 2026140,492
HAIMOVITZ JULESDirectorStock Award(Grant)May 3, 2026152,692
LINDEN JOSEPHINEDirectorStock Award(Grant)May 17, 202615,194
RAIFELD PAVELChief Executive OfficerStock Award(Grant)May 14, 2026285,929

Institution ownership

INVA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.67%12,562,415231.27MSep 29, 2026
Dimensional Fund Advisors LP6.35%4,513,05283.09MSep 29, 2026
Vanguard Portfolio Management LLC5.88%4,177,98276.92MSep 29, 2026
Renaissance Technologies, LLC5.14%3,650,27267.20MSep 29, 2026
State Street Corporation4.92%3,499,69464.43MSep 29, 2026
Vanguard Capital Management LLC4.46%3,172,65058.41MSep 29, 2026

Fund ownership

INVA fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF6.05%4,299,26379.15MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.14%2,231,52641.08MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.75%1,955,20836.00MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.26%1,606,72429.58MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.43%1,018,66618.75MJun 29, 2026
DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio1.42%1,008,11718.56MJul 30, 2026